Resilient Biotics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Resilient Biotics Inc. - overview
Established
2016
Location
Durham, NC, US
Primary Industry
Biotechnology
About
Based in North Carolina, US, and founded in 2016, Resilient Biotics Inc. develops microbiome-based live biotherapeutics that decreases or replaces antibiotics in the animal health industry. The company was co-founded by Christopher Belnap, currently its CEO, and Greg Werner. The company's process combines bioinformatics and machine learning tools in identifying new microbial strains and parsing complex microbiome datasets.
Resilient Biotics flagship product, RBX001, an intranasal and non-antibiotic treatment that prevent bovine respiratory disease (BRD). The company plans to expand product development around similar non-antibiotic microbiome-derived products for other animals. Resilient Biotics also exploring potential therapeutics for swine and poultry.
Current Investors
Viking Global Investors, Elanco Animal Health, Inc., Berkeley Catalyst Fund
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Therapeutic Devices, Analytics & Performance Software
Website
www.resilientbiotics.com
Verticals
Artificial Intelligence, Big Data, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.